ClinicalTrials.gg
RecruitingNCT06657157P-EVOLUTIONUpdated Feb 24, 2026

Peripheral Neuropathy in Patients Receiving Enfortumab Vedotin and Pembrolizumab as First Line Treatment for Metastatic or Locally Advanced Urothelial Carcinoma

An observational study in Urothelial Cancer, sponsored by Comprehensive Cancer Center Munich (CCCM). Recruiting at 4 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-24.

Sponsored by Comprehensive Cancer Center Munich (CCCM) · Observational

How we know · 3 judgments

From the registry’s dates

  • Started Jan 2025; still recruiting 1 year 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
80
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 26 studies in Peripheral Nervous System Diseases with a site in Germany — 6 open to participants now, 7 under way, 5 of them phase 3. Peripheral Nervous System Diseases · Germany.

Planned enrollment
7th of 12
80 · median 115
Started
2025
with 2 others
Observational
12 of 26
2 open now
Registered
23rd of 26
by date
Lead sponsor
2 of 26
Comprehensive Cancer Center Munich (CCCM)

Among the 26 studies in Peripheral Nervous System Diseases with a site in Germany, this one is the 7th largest by planned enrollment of the 12 observational ones that give a count, is one of 3 that started in 2025, is one of 12 observational ones, and was the 23rd registered.

Peripheral Nervous System Diseases

476 studies on the registry are indexed under Peripheral Nervous System Diseases; 103 are open to participants now.

Browse Peripheral Nervous System Diseases studies →

Open to participants now

6 of the 26 studies in Peripheral Nervous System Diseases with a site in Germany are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 65 Peripheral Nervous System Diseases studies recruiting now, 44 (68%) set no upper age limit and 10 (15%) stop at 75 or younger; 8 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Peripheral Nervous System Diseases with a site in Germany, or all of them as a file.
02

Study summary

The P-EVOLUTION trial is a prospective, multicenter, non-interventional observational study aimed at investigating peripheral neuropathy in patients receiving first-line treatment for metastatic or locally advanced urothelial carcinoma with enfortumab vedotin (EV) and pembrolizumab (P). Conducted at two German university hospitals, the study will track the incidence and severity of peripheral neuropathy, its impact on quality of life, and treatment regimen adjustments due to side effects. Approximately 80 patients are expected to be enrolled over one year.

03

Conditions studied

  • Urothelial Cancer

Keywords

  • enfortumab vedotin
  • Pembrolizumab
  • peripheral neuropathy
  • metastatic urothelial carcinoma
  • advanced urothelial carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients meeting the eligibility criteria and are treated at the tertiary care centers LMU Munich and TUM Munich.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients, ≥18 years of age at the time of signing the form (ICF)
  • Patients with confirmed or locally advanced, unresectable urothelial carcinoma
  • Patients who did not receive any systemic treatment for their laUC or mUC (treatment-naïve)
  • Patients who are able to receive enfortumab vedotin and pembrolizumab according to the respective medicinal product information

Exclusion criteria

Exclusion Criteria:

  • Patients with for enfortumab vedotin and/or pembrolizumab
  • Patients who have received a systemic therapy for their laUC or mUC (e.g. platinum-based chemotherapy, checkpoint-inhibitors)
  • Patients who have previously been treated with enfortumab vedotin, other MMAE-based antibody-drug-conjugates or PD-(L)1-
  • Patients who received or adjuvant platinum-based chemotherapy \<12 months ago
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
80 participants (estimated)
Patient registry
No

This study also gives PembrolizumabStudies of PembrolizumabPembrolizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record., Enfortumab vedotinStudies of Enfortumab vedotinEnfortumab vedotin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Incidence of peripheral neuropathy ≥ CTCAE grade 2

    Incidence of peripheral neuropathy ≥ grade 2 at baseline, week 18, week 36, week 52, and at End of Treatment (defined as the administration of the last dose of EV/P) assessed by the Patient Neurotoxicity Questionnaire (PNQ)

    Time frame: baseline, week 18, week 36, week 52, and End of Treatment (defined as the administration of the last dose of EV/P)

Secondary outcomes

  1. Change of degree of sensory, motor and/or autonomic peripheral neuropathy applying the EORTC-CIPN20 questionnaire

    A higher EORTC-CIPN20 score indicates a worse degree of neuropathy.

    Time frame: Baseline, week 18, week 36, week 52, and End of Treatment (defined as the administration of the last dose of EV/P)

  2. Change of Quality of life (QoL) applying the FACT/GOG-NTX questionnaire

    An higher FACT/GOG-NTX score indicates a better QoL.

    Time frame: Baseline, week 18, week 36, week 52, and End of Treatment (defined as the administration of the last dose of EV/P)

  3. Change of neuropathic pain applying the Neuropathic Pain Symptom Inventory (NPSI) questionnaire

    A higher NPSI score indicates more neuropathic pain.

    Time frame: Baseline, week 18, week 36, week 52, and End of Treatment (defined as the administration of the last dose of EV/P)

  4. Change of depression based on the Allgemeine Depressionsskala (ADS)

    A higher ADS value indicates higher degree of depression.

    Time frame: Baseline, week 18, week 36, week 52, and End of Treatment (defined as the administration of the last dose of EV/P)

  5. Time to onset of peripheral neuropathy ≥ CTCAE grade 2

    Time frame: From the administration of the first dose of EV/P to the end of treatment (defined as the administration of the final dose of EV/P), which is expected to occur after approximately one year.

  6. Number of dose reductions, delays or treatment discontinuation due to peripheral neuropathy or other adverse events

    Time frame: From the administration of the first dose of EV/P to the end of treatment (defined as the administration of the final dose of EV/P), which is expected to occur after approximately one year.

  7. Number of cycles of EV + P administered

    Time frame: From the administration of the first dose of EV/P to the end of treatment (defined as the administration of the final dose of EV/P), which is expected to occur after approximately one year.

  8. Change in nerve conduction studies, as measured by neurography, in the right tibial (motor) nerve

    A higher nerve conduction velocity indicates a faster transmission of electrical signal along the nerve. And vice versa.

    Time frame: Baseline, Week 18, End of Treatment (defined as the administration of the final dose of EV/P)

  9. Change in nerve conduction studies, as measured by neurography, in the right sural (sensory) nerve

    A higher nerve conduction velocity indicates a faster transmission of electrical signal along the nerve. And vice versa.

    Time frame: Baseline, Week 18, End of Treatment (defined as the administration of the final dose of EV/P)

  10. Changes in hand force as measured with a Martin-Vigorimeter

    Time frame: Baseline, Week 18, End of Treatment (defined as the administration of the final dose of EV/P)

  11. Changes in sensory perception using a monofilament test

    Time frame: Baseline, Week 18, End of Treatment (defined as the administration of the final dose of EV/P)

  12. Overall survival

    defined as the time from administration of the first dose to date of death due to any cause

    Time frame: From administration of first dose to date of death of any cause, assessed for up to 60 months

  13. real world Progression free survival (rw-PFS)

    rw-PFS, defined as the time from the administration of the first dose of EV/P to the first documented disease progression, as determined by the investigator, or to death from any cause, whichever occurs first, assessed up to 60 months.

    Time frame: From administration of the first dose of EV/P to the first documented disease progression, as determined by the investigator, or to death from any cause, whichever occurs first, assessed up to 60 months.

07

Study locations

4 of 4 sites recruiting
  • Department of Urology, University Hosptial Augsburg
    Augsburg, Bavaria 86156, Germany
    Recruiting
  • Department of Urology, LMU University Hospital, Ludwig-Maximilians-University Munich
    Munich, Bavaria 81377, Germany
    Recruiting
  • Department of Urology, Klinikum rechts der Isar, Technical University Munich
    Munich, Bavaria 81675, Germany
    Recruiting
  • Department of Urology, University Hospital of Würzburg
    Würzburg, Bavaria 97080, Germany
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Dec 2026, 23 months after the start.

Of 38 observational studies under Peripheral Nervous System Diseases, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 93. This study's planned 23 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 19, 2024
First posted
Oct 24, 2024
StartActual
Jan 22, 2025
Primary completionEst.
Dec 2026
CompletionEst.
Feb 2027
Last update
Feb 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06657157
Lead sponsor
Comprehensive Cancer Center Munich (CCCM)
Collaborators
Ludwig-Maximilians - University of Munich, Department of Urology, TUM Klinikum rechts der Isar, Munich, Germany, Department of Urology, Augsburg University Hospital, Augsburg, Germany, Wuerzburg University Hospital
Responsible party
Can Aydogdu, MD (Principal Investigator, Comprehensive Cancer Center Munich (CCCM)) — Principal investigator
First posted
Oct 24, 2024
Start date
Jan 22, 2025
Primary completion
Dec 2026 (estimated)
Completion
Feb 2027 (estimated)
Last update
Feb 24, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion